Related Experiment Video
Updated: Jun 6, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
Intraocular pressure elevation from topical difluprednate use
Kelly Meehan1, Lori Vollmer, Joseph Sowka
1Midwestern University, Arizona College of Optometry, 19555 N. 59th Avenue, Glendale, AZ 85308, USA. kellymeehanod@gmail.com
Difluprednate ophthalmic emulsion can cause significant intraocular pressure (IOP) increases, even in patients not previously sensitive to steroids. Clinicians should monitor IOP closely when prescribing this potent anti-inflammatory medication.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Difluprednate ophthalmic emulsion 0.05% is a potent topical steroid for ocular inflammation.
- It is associated with a potential increase in intraocular pressure (IOP).
Observation:
- Two cases of patients experiencing significant IOP elevation after switching to difluprednate 0.05% are presented.
- One patient with traumatic uveitis showed an IOP increase from 9 to 48 mmHg.
- Another patient with scleritis experienced an IOP rise from 18 to 34 mmHg.
Findings:
- Difluprednate 0.05% can cause rapid and substantial increases in IOP.
- These pressure elevations were successfully managed by discontinuing the medication and using IOP-lowering agents.
Implications:
- Clinicians must be aware of the risk of significant IOP increase with difluprednate ophthalmic emulsion.
- Close monitoring of IOP is crucial for patients using this medication, especially off-label.
- This highlights the need for careful patient management and consideration of potential side effects.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview
Angle Closure Glaucoma: Treatment
Ophthalmic Drug Delivery Systems
Increased Intracranial Pressure l: Introduction
Increased Intracranial Pressure ll: Pathophysiology